AstraZeneca was told by the CDSCO panel to submit an analysis of clinical data specific to the Asian and Indian population regarding their drug Durvalumab. The panel emphasized the importance of understanding how the drug affects these populations to ensure its safety and efficacy. By analyzing this data, AstraZeneca can provide more targeted and personalized treatment options for patients in these regions. The use of cookies on this site was also highlighted, with users agreeing to their use for analytics and advertising purposes. More information on cookie settings can be found in the Cookie Policy.
Source link
CDSCO Panel Tells AstraZeneca on Durvalumab
